Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

Olr363 Inhibitors

Olr363 inhibitors represent a specialized class of chemical compounds primarily characterized by their interaction with the Olr363 receptor, a specific olfactory receptor type in the G protein-coupled receptor (GPCR) superfamily. Olr363, like other olfactory receptors, is integral to the detection and transduction of chemical signals, primarily volatile molecules, into neural signals that contribute to the sense of smell. The inhibitors of Olr363 are designed to modulate the activity of this receptor by preventing its activation by natural ligands, thereby altering the signal transduction pathways that are initiated upon receptor-ligand binding. This class of inhibitors often comprises molecules with structural features that allow them to competitively or non-competitively bind to the active site or allosteric sites of Olr363, thereby hindering the receptor's ability to interact with its natural agonists.

Chemically, Olr363 inhibitors can vary widely in their molecular structure, but they generally share certain characteristics that enable them to effectively target the receptor. These inhibitors may possess hydrophobic moieties that facilitate interaction with the hydrophobic binding pocket of the Olr363 receptor. Additionally, many Olr363 inhibitors are designed with specific functional groups that can engage in hydrogen bonding or van der Waals interactions with key amino acid residues in the receptor's binding domain. The efficacy and specificity of these inhibitors are often influenced by their molecular conformation, which must complement the three-dimensional structure of the Olr363 receptor. The development and study of Olr363 inhibitors typically involve a deep understanding of receptor-ligand interactions, binding affinities, and the structural dynamics of the receptor, making them a fascinating subject of study within the field of chemical biology and receptor chemistry.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lapatinib

231277-92-2sc-353658
100 mg
$412.00
32
(1)

Dual EGFR and HER2 inhibitor, potentially disrupts signaling in certain cancers.

Everolimus

159351-69-6sc-218452
sc-218452A
5 mg
50 mg
$128.00
$638.00
7
(1)

mTOR inhibitor, may limit cell growth and proliferation in various cancers.

Sorafenib

284461-73-0sc-220125
sc-220125A
sc-220125B
5 mg
50 mg
500 mg
$56.00
$260.00
$416.00
129
(3)

Multi-kinase inhibitor, could affect cell proliferation and angiogenesis in tumors.

Afatinib-d4

850140-72-6 (unlabeled)sc-481821
10 mg
$4665.00
(0)

EGFR inhibitor, potentially effective in non-small cell lung carcinoma.

Osimertinib

1421373-65-0sc-507355
5 mg
$86.00
(0)

EGFR inhibitor, may be effective in T790M-positive lung cancer.

Regorafenib

755037-03-7sc-477163
sc-477163A
25 mg
50 mg
$320.00
$430.00
3
(0)

Multi-kinase inhibitor, potentially effective in colorectal cancer and GIST.

Trametinib

871700-17-3sc-364639
sc-364639A
sc-364639B
5 mg
10 mg
1 g
$112.00
$163.00
$928.00
19
(1)

MEK inhibitor, could inhibit cell proliferation in melanoma with BRAF mutations.

Ibrutinib

936563-96-1sc-483194
10 mg
$153.00
5
(0)

BTK inhibitor, potentially effective in certain B-cell malignancies.

Lenvatinib

417716-92-8sc-488530
sc-488530A
sc-488530B
5 mg
25 mg
100 mg
$178.00
$648.00
$1657.00
3
(0)

Multi-kinase inhibitor, might affect thyroid and renal cell carcinoma.

XL-184 free base

849217-68-1sc-364657
sc-364657A
5 mg
10 mg
$92.00
$204.00
1
(1)

MET, VEGFR2, RET inhibitor, could be effective in medullary thyroid cancer.